Western medicine’s approach to cancer treatment is based on profit, not safety and effectiveness. This became abundantly clear to me while designing tamoxifen derivatives for the drug industry.

Tamoxifen, like estrogen, binds to the estrogen receptor. In its early days, it was thought that this would prevent excess estrogen binding and therefore halt cancer. It was unleashed to the public as an anti-cancer drug.

Mayo Clinic got excited and announced that, “Tamoxifen (Nolvadex) — has been officially approved by the Food and Drug Administration (FDA) to help protect high-risk women from getting breast cancer. It's generally taken for five years.”

As time passed, tamoxifen proved to be the anti-cancer drug that actually caused cancer. As a drug chemist, I was prompted to fix Big Pharma’s dirty secret.

For one year, I attempted to offset the cancer side effect of tamoxifen by designing chemical cousins of it. Such attempts failed. All of its molecular relatives initiated cancer. The project was cancelled. The secret was kept. Tamoxifen remained on the market and continued its cancer scourge among unsuspecting victims.

The American Academy of Family Physicians attempted to warn physicians by announcing, “Incidence of endometrial cancer (cancer of the womb lining) almost doubled for those taking the drug [Tamoxifen] for one to two years. Taking it over a five year period: Cases quadrupled.”  

Science rarely has a voice loud enough to penetrate Big Pharma’s overwhelming marketing chatter. The industry continues to push the billion dollar profit-puller as the first line of defense against cancer. Avoid the hype, avoid the cancer.